Neurology

Biotech

New data for Genentech’s MS drug shows benefit of early treatment

By Kate Sheridan

Single white lab mouse
In the Lab

Can building a better research mouse open the black box of Alzheimer’s?

By Kate Sheridan

Ear Hair Cells
In the Lab

After decades of false starts, Harvard team says it’s found the ‘missing link’ in how we hear

By Eric Boodman

ACT UP 1989
Health

As Alzheimer’s drug developers give up on today’s patients, where is the outrage?

By Sharon Begley

Empty pipeline
Pharma

That pathetic Alzheimer’s pipeline? It’s even worse than you think

By Sharon Begley

Special Report

An Appalachian odyssey: Hunting for ALS genes along a sprawling family tree

By Eric Boodman

In the Lab

Drugs aimed at a sliver of Parkinson’s patients may benefit many more than thought — and boost a biotech

By Sharon Begley

First Opinion

Finding new treatments for Parkinson’s and Alzheimer’s shouldn’t be up to pharma alone

By Allan Hugh Cole Jr.

Epidiolex
Pharma

FDA approves country’s first medicine made from marijuana

By Andrew Joseph

HHV-6: Radioactive Isotope
In the Lab

New study supports long-dismissed idea: Herpes viruses could play role in Alzheimer’s

By Sharon Begley

Health

Can this doctor figure out how to stop Alzheimer’s before it starts?

By Joshua Kendall

Dr. Alice Flaherty 02
Heavyweights

It’s not ‘all in your head’: When other doctors give up on patients, a boundary-breaking neurologist treats them

By Eric Boodman

Sarah Benoit 01
Pharmalot

ALS patients losing time and hope as they wait for insurers to cover a pricey new drug

By Ed Silverman

Amgen
Biotech

Amgen’s new migraine drug will cost 30 percent less than Wall Street expected

By Damian Garde

Epidiolex
Health

Panel recommends FDA approval of epilepsy drug derived from marijuana

By Andrew Joseph

UT Health Medical School
In the Lab

In a bid to promote stem cell therapies, health officials open a new door for promising contenders

By Andrew Joseph

Pharmalot
Pharmalot

New migraine drugs may give insurers a headache

By Ed Silverman

Pharmalot

Pharmalittle: HHS drug-pricing adviser holds conflicts; should Alzheimer’s be redefined?

By Ed Silverman

Crispr and the brain
In the Lab

Scientists are thinking the unthinkable: CRISPR might one day reverse devastating brain diseases

By Sharon Begley

Victor Gurewich
In the Lab

At 88, this doctor won’t give up on a long-ignored treatment for strokes and heart attacks

By Karen Weintraub

Richard Vinci
Biotech

Trials for potential ALS treatment using stem cells spark cautious hope

By Jonathan Saltzman — Boston Globe

Spine Atlas
First Opinion

A 3-D spinal cord atlas will improve treatment of difficult injuries

By Marc D. Moisi, R. Shane Tubbs, and Ricardo Lockette

New Brain Scanner
Health

Worn like a helmet, a new brain scanner aims to make it easier to treat kids with epilepsy

By Megan Thielking

EKG
Health

Watch: Webcast on heart and brain diseases in women

By STAT staff

Tai Chi and brain
Health

Too good to be true? Experts clash on whether hitting the gym helps the brain

By Sharon Begley

State of (Trump's) Mind

Is Trump’s memory declining? Simple tests during his physical could answer that question

By Sharon Begley

Bugula neritina
Biotech

‘Failed’ Alzheimer’s drug looks better with additional analysis, Neurotrope says

By Sharon Begley

Trump Announces U.S. Will Recognize Jerusalem
First Opinion

I’m a brain specialist. I think Trump should be tested for a degenerative brain disease

By Ford Vox

Paolo Zamboni
Health

Scientist concedes his controversial MS therapy, once a source of great hope, is ‘largely ineffective’

By Helen Branswell

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy